0QOI.LSE Newron Pharmaceuticals S.p.A.
- Market cap
- GBP 201M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QOI.LSE undervalued?
Graham numberThe Graham number of Newron Pharmaceuticals S.p.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Newron Pharmaceuticals S.p.A. fundamental analysis
No fundamental analysis for Newron Pharmaceuticals S.p.A. yet.
Newron Pharmaceuticals S.p.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizo…
Full company profileNewron Pharmaceuticals S.p.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Newron Pharmaceuticals S.p.A. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.73M | 13.4M | 4.03M | 7.04M | 5.26M | 5.76M | 6.09M | 9.06M | 51.4M | 19.3M | 12.7M |
| Gross Profit | 6.73M | 13.4M | 4.03M | 7.04M | 5.26M | 5.76M | 6.09M | 9.06M | 51.4M | 19.1M | 12.8M |
| Operating Income | -15.3M | -4.10M | -15.0M | -20.9M | -18.1M | -12.4M | -13.3M | -11.6M | 26.2M | -4.73M | -66.1M |
| EBITDA | -15.3M | -4.05M | -14.8M | -20.7M | -17.8M | -12.2M | -13.1M | -11.4M | 26.4M | -4.55M | -65.7M |
| Net Income | -15.2M | -5.28M | -15.0M | -20.2M | -21.0M | -14.9M | -17.5M | -16.2M | 15.8M | -13.3M | -65.2M |
| EPS | -1.04 | -0.32 | -0.84 | -1.13 | -1.18 | -0.84 | -0.98 | -0.91 | 0.77 | -0.67 | -3.18 |
| Balance Sheet | |||||||||||
| Total Assets | 56.6M | 73.0M | 60.0M | 60.3M | 51.2M | 50.5M | 37.2M | 25.9M | 63.9M | 40.0M | 40.4M |
| Total Liabilities | 6.65M | 4.73M | 5.16M | 23.5M | 34.0M | 47.4M | 51.2M | 55.8M | 62.5M | 51.2M | 52.1M |
| Shareholders' Equity | 49.7M | 67.7M | 54.8M | 36.8M | 17.2M | 3.11M | -14.0M | -29.9M | 1.46M | -11.1M | -11.7M |
| Cash & Short-term Investments | 46.5M | 60.1M | 43.9M | 39.2M | 31.3M | 34.6M | 22.8M | 12.6M | 9.83M | 28.9M | 33.0M |
| Total Debt | 364K | - | 125K | 16.8M | 26.2M | 42.9M | 45.5M | 48.2M | 50.5M | 38.1M | 39.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.6M | -8.40M | -16.0M | -22.0M | -15.6M | -11.4M | -11.1M | -10.1M | -17.6M | 32.6M | -42.8M |
| Capital Expenditure | 69.0K | 24.0K | 34.0K | 51.0K | 34.0K | 20.0K | 18.0K | 11.0K | 13.0K | 47.3K | 83.6K |
| Free Cash Flow | -19.7M | -8.43M | -16.0M | -22.0M | -15.6M | -11.5M | -11.1M | -10.2M | -17.6M | 32.5M | -42.9M |
| Ratios | |||||||||||
| ROE | -30.6% | -7.8% | -27.4% | -54.9% | -121.8% | -479.6% | - | - | 1,086.6% | - | - |
| ROA | -26.9% | -7.2% | -25.1% | -33.5% | -41.0% | -29.5% | -47.0% | -62.7% | 24.8% | -33.3% | -161.3% |
| Net Profit Margin | -226.5% | -39.3% | -373.5% | -287.1% | -399.4% | -258.6% | -287.1% | -179.1% | 30.8% | -69.2% | -513.4% |
| Debt to Equity | 0.01x | - | 0.00x | 0.46x | 1.52x | 13.82x | - | - | 34.62x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Newron Pharmaceuticals S.p.A. dividends
Newron Pharmaceuticals S.p.A. has not paid dividends in the last 9 fiscal years.
Who owns Newron Pharmaceuticals S.p.A.
- Insiders 12.84%
- Institutions 12.45%
- Public & others 74.71%
- Shares outstanding 17.8M
- Free float 18.9M
Newron Pharmaceuticals S.p.A. company profile
- Company name
- Newron Pharmaceuticals S.p.A.
- Ticker
- 0QOI.LSE
- ISIN
- IT0004147952
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 27
- Fiscal year end
- December
- Address
- Via Antonio Meucci 3, Bresso, MI, Italy, 20091
- Phone
- 39 02 610 3461
- Website
- newron.com
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Newron Pharmaceuticals S.p.A. management
5- Mr. Stefan WeberCEO & Executive Director · born 1965
- Mr. Roberto GalliChief Financial Officer
- Mr. Filippo MoriggiaVice President of Operations
- Dr. Ravi Anand M.D., Ph.D.Chief Medical Officer · born 1957
- Ms. Laura FaravelliVice President of Business Development